Postmarketing Study to Assess the Safety of Nivolumab as a First- and Second-line Treatment in Patients With Metastatic Melanoma or as a Second-line Treatment for Metastatic Lung Cancer (Squamous and Nonsquamous), Metastatic Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adult Patients in Mexico

Trial Profile

Postmarketing Study to Assess the Safety of Nivolumab as a First- and Second-line Treatment in Patients With Metastatic Melanoma or as a Second-line Treatment for Metastatic Lung Cancer (Squamous and Nonsquamous), Metastatic Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adult Patients in Mexico

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jun 2017 Planned initiation date changed from 16 Jun 2017 to 31 Jul 2017.
    • 24 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top